Abstract 2533
Background
ICIs are pivotal therapies in the treatment of pts with R/M HNSCC. The dismal OS of some pts underscores the need to detect pre-treatment prognostic scores.
Methods
Pts with R/M HNSCC receiving pembrolizumab (P) or nivolumab (N) were included in this retrospective analysis. We analyzed the impact of the following pre-treatment variables for OS using a Cox proportional hazards regression model: drug type, age, sex, tumor site, line of therapy, p-16, albumin (alb), hemoglobin (Hb), lactic dehydrogenase (LDH), lymphocyte count (LC), platelets (PLT), and neutrophil counts (NC).
Results
66 pts (55%) treated with N and 55 (45%) with P were included. Characteristics: Sex: Male 100 pts (83%), female 21 pts (17%); Mean Age: 62 (SD 11); Performance Status 0-1: 63 pts (52%), 2-3: 58 pts (48%); Line of therapy, 1: 43 pts (36%), 2: 58 pts (48%), 3-4: 20 pts (16%); P-16: positive 44 pts (36%), negative 77 pts (64%); Tumor site: oropharynx 54 pts (45%), oral cavity 23 pts (19%), larynx 16 pts (13%), other 28 pts (23%); Response: complete 11 pts (9%), partial 3 pts (2%), stable disease 47 pts (39%); and disease progression: 60 pts (50%). The OS at 1 and 2 years were 52% (95% confidence interval (CI), 43%-62%) and 27% (CI 17%-42%), respectively. Age, sex, PLT, NC, LC, p-16, alb, Hb, and LDH were included in the multivariable Cox model. Adjusted hazard ratio estimates are: P-16: 0.53 (CI 0.3-0.95, P = 0.03); LC: 0.67 (CI 0.46-0.97, P = 0.03); NC: 1.25 (CI 1.01-1.56, P = 0.04); LDH: 1.67 (CI 1.01-2.78, P = 0.04); Hb: 1.69 (CI 1.00-2.87, P = 0.05); alb: 1.69 (CI 0.94-3.02, P = 0.08); PLT: 1.06 (CI 0.82, 1.37, P = 0.7); Age: 1.02 (CI 0.78-1.34, P = 0.9); and Sex: 0.98 (CI 0.5-1.91, P = 0.9). This model was used to create a nomogram based prognostic score for 1 and 2 year OS probability and median OS time. Internal model validation using bootstrapped based bias corrected estimates showed Nagelkerke’s R2 = 0.18, calibration slope of 0.67, and C-index of 0.7.
Conclusions
Pre-treatment LC, NC as well as LDH, Hb, alb, and p-16 had the largest impact on OS based on a prognostic nomogram. The nomogram may help treatment decisions regarding ICI use in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract